Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
MidasMeme
MidasMeme Sep. 14 at 9:00 AM
$GTLB $AZN $TE $WTI $MELI kk
0 · Reply
notreload_ai
notreload_ai Sep. 14 at 8:32 AM
Citi calls $OLMA drop after $AZN SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use. https://notreload.xyz/xy/citi-calls-olema-selloff-after-serena-4-excessive/
0 · Reply
tomgunny
tomgunny Sep. 12 at 11:27 PM
$AZN Set limit buy order 2500 shares @$40
0 · Reply
Bigbossmann
Bigbossmann Sep. 12 at 3:08 PM
$AZN Motley Crew
0 · Reply
tomgunny
tomgunny Sep. 12 at 12:22 PM
$AZN gap down Monday lol
0 · Reply
Kingjake26
Kingjake26 Sep. 12 at 4:08 AM
$AZN I will Let you in on a secret. Check out CADL and can-2409 and can-3110 . It’s early but they have something special for the breast cancer
0 · Reply
topstockalerts
topstockalerts Sep. 12 at 1:59 AM
AstraZeneca said its breast cancer drug Etcamah failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial, sending its U.S.-listed shares down about 3% in after-hours trading. The trial evaluated Etcamah in combination with palbociclib in previously untreated patients with advanced breast cancer. While the combination showed a numerical improvement in progression-free survival, it did not achieve the study’s primary goal, and AstraZeneca said it will provide the full trial results at a later date. The setback comes only a week after the FDA granted accelerated approval for Etcamah to be used alongside certain CDK4/6 inhibitors, a class of targeted cancer drugs. The failed trial could raise questions about the drug’s broader effectiveness in earlier-line treatment, although the company continues to have an approved use for the therapy under the FDA’s accelerated pathway. $AZN
0 · Reply
Scrapps64
Scrapps64 Sep. 11 at 11:05 PM
$AZN
0 · Reply
FBP
FBP Sep. 11 at 10:56 PM
$AZN almost worth buying. Almost.. index still outperforming long term
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 11 at 10:11 PM
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus $AZN $PVAL $AVDE https://stocktwits.com/news/equity/markets/azn-stock-slips-after-hours-following-latest-late-stage-oncology-trial-miss-executive-disappointed-reiterates-breast-cancer-focus/cZtXD0GRBb0
0 · Reply
Latest News on AZN
AstraZeneca reports results from DESTINY-Lung04 trial

2026-09-14T09:30:32.000Z - 7 minutes ago

AstraZeneca reports results from DESTINY-Lung04 trial

AstraZeneca reports updated exploratory results from ADAURA trial

2026-09-14T09:30:09.000Z - 7 minutes ago

AstraZeneca reports updated exploratory results from ADAURA trial

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Mon, 14 Sep 2026 02:02:00 -0400 - 3 hours ago

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Olema selloff on AstraZeneca miss a buying opportunity, says Citi

2026-09-13T23:20:07.000Z - 10 hours ago

Olema selloff on AstraZeneca miss a buying opportunity, says Citi

OLMA

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

Sun, 13 Sep 2026 06:02:22 -0400 - 23 hours ago

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

AZN Looks 12.0% Undervalued on GF Value™ as Dividend Remains Attractive

2026-09-11T23:26:11.000Z - 2 days ago

AZN Looks 12.0% Undervalued on GF Value™ as Dividend Remains Attractive

AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer

2026-09-11T21:01:17.000Z - 2 days ago

AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer

Astrazeneca's breast cancer drug fails late-stage trial

Fri, 11 Sep 2026 16:34:06 -0400 - 2 days ago

Astrazeneca's breast cancer drug fails late-stage trial

AstraZeneca down 2% at $157 after SERENA-4 trial update

2026-09-11T20:30:23.000Z - 2 days ago

AstraZeneca down 2% at $157 after SERENA-4 trial update

AstraZeneca says SERENA-4 trial did not meet primary objective

2026-09-11T20:25:13.000Z - 2 days ago

AstraZeneca says SERENA-4 trial did not meet primary objective

Running costs of Covid vaccine damage scheme double the amount paid to victims

2026-09-11T17:45:14.267Z - 2 days ago

Running costs of Covid vaccine damage scheme double the amount paid to victims

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

2026-09-11T16:06:19.000Z - 2 days ago

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Stocks and Shares ISA returns by 2035: AZN merger cloud changes the maths

2026-09-11T08:03:30.000Z - 3 days ago

Stocks and Shares ISA returns by 2035: AZN merger cloud changes the maths

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

2026-09-10T10:26:47.000Z - 3 days ago

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough

2026-09-09T18:02:36.000Z - 4 days ago

AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough

AZN Looks 12.5% Undervalued on GF Value™

2026-09-09T15:59:52.000Z - 4 days ago

AZN Looks 12.5% Undervalued on GF Value™

AstraZeneca drug reduces lung disease flare-ups in late-stage trials

Wed, 09 Sep 2026 07:05:59 -0400 - 4 days ago

AstraZeneca drug reduces lung disease flare-ups in late-stage trials

Lighting Round: I have never liked Grab Holdings, says Jim Cramer

2026-09-09T00:06:29.000Z - 5 days ago

Lighting Round: I have never liked Grab Holdings, says Jim Cramer

Cramer's lightning round: 'I am not going to put my money on AstraZeneca'

2026-09-08T22:55:02.000Z - 5 days ago

Cramer's lightning round: 'I am not going to put my money on AstraZeneca'

AstraZeneca initiated with an Outperform at RBC Capital

2026-09-08T20:21:03.000Z - 5 days ago

AstraZeneca initiated with an Outperform at RBC Capital

AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test

2026-09-08T16:35:42.000Z - 5 days ago

AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test

Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study

2026-09-08T15:16:13.000Z - 5 days ago

Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study

AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Potential Soars

2026-09-08T15:10:39.000Z - 5 days ago

AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Potential Soars

AstraZeneca Transcript: Investor update

Sep 8, 2026, 11:00 AM EDT - 5 days ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Sep 8, 2026, 11:00 AM EDT - 5 days ago

AstraZeneca Slides: Investor update

AZN Looks 10.1% Undervalued on GF Value™ as Dividend Remains Attractive

2026-09-08T14:40:53.000Z - 5 days ago

AZN Looks 10.1% Undervalued on GF Value™ as Dividend Remains Attractive

AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD

2026-09-08T14:29:07.000Z - 5 days ago

AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD

AZN Looks 10.1% Undervalued on GF Value™ Amid Strong Dividend Sustainability

2026-09-08T13:27:06.000Z - 5 days ago

AZN Looks 10.1% Undervalued on GF Value™ Amid Strong Dividend Sustainability

AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups

Tue, 08 Sep 2026 09:18:00 -0400 - 5 days ago

AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups

Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint

2026-09-08T13:15:32.000Z - 5 days ago

Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint

AMGN

AstraZeneca's cancer drug combo hits main survival goal in late-stage trial

Tue, 08 Sep 2026 09:15:15 -0400 - 5 days ago

AstraZeneca's cancer drug combo hits main survival goal in late-stage trial

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

2026-09-08T13:05:47.000Z - 5 days ago

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

AMGN

AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

2026-09-08T12:18:36.000Z - 5 days ago

AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca says tozorakimab demonstrates reduction in COPD exacerbations

2026-09-08T11:55:07.000Z - 5 days ago

AstraZeneca says tozorakimab demonstrates reduction in COPD exacerbations

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Tue, 08 Sep 2026 07:50:00 -0400 - 5 days ago

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

Tue, 08 Sep 2026 07:45:17 -0400 - 5 days ago

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast Cancer

2026-09-08T10:17:21.000Z - 5 days ago

AstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast Cancer

AZN Looks 10.4% Undervalued on GF Value™ as Dividend Sustainability Shines

2026-09-05T12:57:55.000Z - 8 days ago

AZN Looks 10.4% Undervalued on GF Value™ as Dividend Sustainability Shines

ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

2026-09-04T23:03:00.000Z - 9 days ago

ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

Guardant Health Announces Landmark FDA Approval of Guardant360 CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in Advanced Breast Cancer

2026-09-04T22:10:00.000Z - 9 days ago

Guardant Health Announces Landmark FDA Approval of Guardant360 CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in Advanced Breast Cancer

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

2026-09-04T14:09:35.000Z - 9 days ago

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

AZN Looks 9.4% Undervalued on GF Value™ Amid Strong Dividend Profile

2026-09-04T13:31:13.000Z - 9 days ago

AZN Looks 9.4% Undervalued on GF Value™ Amid Strong Dividend Profile

AstraZeneca gets orphan designation for treatment of hepatocellular carcinoma

2026-09-04T12:00:31.000Z - 9 days ago

AstraZeneca gets orphan designation for treatment of hepatocellular carcinoma

C4X Discovery Holdings PLC: C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement

2026-09-04T07:06:00.000Z - 10 days ago

C4X Discovery Holdings PLC: C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement

The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power

2026-09-03T12:53:00.000Z - 10 days ago

The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power

Top Stock Reports for AMD, Costco & AstraZeneca

2026-09-02T20:36:00.000Z - 11 days ago

Top Stock Reports for AMD, Costco & AstraZeneca

AZN Looks 10.6% Undervalued on GF Value™ as Dividend Remains Sustainable

2026-09-01T20:01:14.000Z - 12 days ago

AZN Looks 10.6% Undervalued on GF Value™ as Dividend Remains Sustainable

AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win

2026-09-01T17:19:20.000Z - 12 days ago

AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win

AZN Looks 10.5% Undervalued on GF Value™ as Dividend Remains Secure

2026-09-01T12:35:16.000Z - 12 days ago

AZN Looks 10.5% Undervalued on GF Value™ as Dividend Remains Secure

AZN Looks 10.5% Undervalued on GF Value™ as Dividend Remains Attractive

2026-09-01T12:30:32.000Z - 12 days ago

AZN Looks 10.5% Undervalued on GF Value™ as Dividend Remains Attractive

MidasMeme
MidasMeme Sep. 14 at 9:00 AM
$GTLB $AZN $TE $WTI $MELI kk
0 · Reply
notreload_ai
notreload_ai Sep. 14 at 8:32 AM
Citi calls $OLMA drop after $AZN SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use. https://notreload.xyz/xy/citi-calls-olema-selloff-after-serena-4-excessive/
0 · Reply
tomgunny
tomgunny Sep. 12 at 11:27 PM
$AZN Set limit buy order 2500 shares @$40
0 · Reply
Bigbossmann
Bigbossmann Sep. 12 at 3:08 PM
$AZN Motley Crew
0 · Reply
tomgunny
tomgunny Sep. 12 at 12:22 PM
$AZN gap down Monday lol
0 · Reply
Kingjake26
Kingjake26 Sep. 12 at 4:08 AM
$AZN I will Let you in on a secret. Check out CADL and can-2409 and can-3110 . It’s early but they have something special for the breast cancer
0 · Reply
topstockalerts
topstockalerts Sep. 12 at 1:59 AM
AstraZeneca said its breast cancer drug Etcamah failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial, sending its U.S.-listed shares down about 3% in after-hours trading. The trial evaluated Etcamah in combination with palbociclib in previously untreated patients with advanced breast cancer. While the combination showed a numerical improvement in progression-free survival, it did not achieve the study’s primary goal, and AstraZeneca said it will provide the full trial results at a later date. The setback comes only a week after the FDA granted accelerated approval for Etcamah to be used alongside certain CDK4/6 inhibitors, a class of targeted cancer drugs. The failed trial could raise questions about the drug’s broader effectiveness in earlier-line treatment, although the company continues to have an approved use for the therapy under the FDA’s accelerated pathway. $AZN
0 · Reply
Scrapps64
Scrapps64 Sep. 11 at 11:05 PM
$AZN
0 · Reply
FBP
FBP Sep. 11 at 10:56 PM
$AZN almost worth buying. Almost.. index still outperforming long term
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 11 at 10:11 PM
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus $AZN $PVAL $AVDE https://stocktwits.com/news/equity/markets/azn-stock-slips-after-hours-following-latest-late-stage-oncology-trial-miss-executive-disappointed-reiterates-breast-cancer-focus/cZtXD0GRBb0
0 · Reply
RazorbackAJ
RazorbackAJ Sep. 11 at 9:51 PM
$OLMA Buyiny Olma here on the overreaction from $AZN results. Current trailing stop under $7. Follow for setups like this — exact entries, precise stop levels, nothing vague. This is how I trade, not financial advice.
0 · Reply
RazorbackAJ
RazorbackAJ Sep. 11 at 8:54 PM
$OLMA Down because $AZN trial failure
1 · Reply
notreload_ai
notreload_ai Sep. 11 at 8:49 PM
$AZN said SERENA-4 did not show a statistically significant PFS gain for Etcamah plus palbociclib in first-line advanced ER+ breast cancer. https://notreload.xyz/xy/astrazeneca-serena-4-trial-misses-primary-endpoint/
0 · Reply
Loxxx
Loxxx Sep. 10 at 7:48 PM
$AZN down 10 % this year and up like 1.5 % one year, almost the same on 3 year (1.7 %). What will next report say about the future?
0 · Reply
Chipwars
Chipwars Sep. 10 at 5:59 PM
$AZN since Cramer said "don't buy" Astrazeneca has gone up nicely. Now there is more good news : https://www.theglobeandmail.com/investing/markets/stocks/JAZZ/pressreleases/4543102/amgn-azn-drug-combo-shows-survival-benefit-in-lung-cancer-study/
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 10 at 4:57 PM
$SLS $JNJ $AZN 🤐 Is BO related. All will be revealed shortly. Hold with Conviction. I don’t the exact minute but I expect a T1 halt before next official PR. It’s coming!✌️🙏❤️‍🩹
0 · Reply
Chipwars
Chipwars Sep. 10 at 2:55 PM
$AZN AstraZeneca drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. https://www.proactiveinvestors.co.uk/companies/news/1098291/astrazeneca-copd-data-back-citi-s-7b-peak-sales-case-1098291.html
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Sep. 9 at 7:28 PM
$AZN so this is the result after Dr. Marc Siegel on Fox News speaks about their breakthrough drugs... Hmmm
0 · Reply
Anthonyp165
Anthonyp165 Sep. 9 at 3:05 PM
$AZN Is there any news for the drop in stock price? I was able to sell 600 shares from on a gain from QQQI. Thank god I sold 9/18 $165 options yesterday for $2.05. this is going to take time and patience to exit.
0 · Reply
Anthonyp165
Anthonyp165 Sep. 9 at 1:17 PM
$AZN Wow, AZN is weak again this morning
0 · Reply